Parsemus Foundation: Metformin Drastically Reduces COVID Hospitalization, Study Shows
Retrieved on:
Thursday, August 18, 2022
Health, Consumer, Diabetes, Infectious Diseases, Clinical Trials, Pharmaceutical, Hispanic, Parsemus Foundation, Â, The New England Journal of Medicine, Lissner, University, Inflammation, Metformin, Death, Assistant, COVID, Research, COVID-19, Foundation, MTOR, Solution, Fluvoxamine, Health, Pharmaceutical industry, Hospital
The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.
Key Points:
- The results were published Aug. 18 in the New England Journal of Medicine, according to Parsemus Foundation.
- But you dont know whether its just coincidence until you go back to the beginning, with a rigorous randomized trial.
- Parsemus Foundation was joined by two larger foundations also eager to see low-cost, globally-accessible medications put to the test.
- More information on the Parsemus Foundation and the work presented here can be found at: https://www.parsemus.org/humanhealth/covid-19/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005438/en/